全文获取类型
收费全文 | 28432篇 |
免费 | 1915篇 |
国内免费 | 127篇 |
专业分类
耳鼻咽喉 | 376篇 |
儿科学 | 660篇 |
妇产科学 | 523篇 |
基础医学 | 3655篇 |
口腔科学 | 951篇 |
临床医学 | 2305篇 |
内科学 | 7275篇 |
皮肤病学 | 785篇 |
神经病学 | 2609篇 |
特种医学 | 696篇 |
外科学 | 4619篇 |
综合类 | 179篇 |
一般理论 | 12篇 |
预防医学 | 1716篇 |
眼科学 | 825篇 |
药学 | 1456篇 |
1篇 | |
中国医学 | 61篇 |
肿瘤学 | 1770篇 |
出版年
2023年 | 257篇 |
2022年 | 172篇 |
2021年 | 1026篇 |
2020年 | 602篇 |
2019年 | 958篇 |
2018年 | 1136篇 |
2017年 | 641篇 |
2016年 | 744篇 |
2015年 | 927篇 |
2014年 | 1232篇 |
2013年 | 1526篇 |
2012年 | 2500篇 |
2011年 | 2567篇 |
2010年 | 1312篇 |
2009年 | 1193篇 |
2008年 | 1963篇 |
2007年 | 1987篇 |
2006年 | 1853篇 |
2005年 | 1645篇 |
2004年 | 1417篇 |
2003年 | 1193篇 |
2002年 | 1134篇 |
2001年 | 162篇 |
2000年 | 134篇 |
1999年 | 168篇 |
1998年 | 189篇 |
1997年 | 150篇 |
1996年 | 124篇 |
1995年 | 164篇 |
1994年 | 135篇 |
1993年 | 126篇 |
1992年 | 100篇 |
1991年 | 74篇 |
1990年 | 60篇 |
1989年 | 66篇 |
1988年 | 57篇 |
1987年 | 42篇 |
1986年 | 54篇 |
1985年 | 43篇 |
1984年 | 65篇 |
1983年 | 47篇 |
1982年 | 73篇 |
1981年 | 68篇 |
1980年 | 50篇 |
1979年 | 36篇 |
1978年 | 32篇 |
1977年 | 36篇 |
1976年 | 31篇 |
1974年 | 28篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
1.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
2.
3.
Francisco Javier P rez Lara Maria Belen Jimenez Martinez Francisco Pozo Mu oz res Fontalba Navas Rogelio Garcia Cisneros Maria Jose Garcia Larrosa Ignacio Garcia Delgado Maria del Mar Callejon Gil 《World Journal of Clinical Cases》2021,9(23):6582-6590
The coronavirus disease 2019, which is caused by severe acute respiratory syndrome coronavirus 2, was first identified in December 2019 in Wuhan, China, and has since spread rapidly, evolving into a full-blown pandemic. We would like to report our experience after 1 year of this pandemic in the surgical service of a district hospital in Spain. There have been many changes (including new protocols) that our service and the hospital have undergone, to adapt to the new situation. We believe that this experience can be useful for other professionals who have lived and are living a similar situation. 相似文献
4.
Antonio Montalvo Afonso Fernando Ruiz Juretschke Rosario González Rodrigálvarez Olga Mateo Sierra Begoña Iza Vallejo Roberto García Leal Marc Valera Melé Vicente Casitas Hernando Jose Manuel Hernández Poveda Carlos Fernández Carballal 《Neurocirugía (Asturias, Spain)》2021,32(1):1-9
Background and objectivesThe treatment of deafferentation pain by spinal DREZotomy is a proven therapeutic option in the literature. In recent years, use of DREZotomy has been relegated to second place due to the emergence of neuromodulation therapies. The objectives of this study are to demonstrate that DREZotomy continues to be an effective and safe treatment and to analyse predictive factors for success.Patients and methodsA retrospective study was conducted of all patients treated in our department with spinal DREZotomy from 1998 to 2018. Bulbar DREZotomy procedures were excluded. A visual analogue scale (VAS) and the reduction of routine medication were used as outcome variables. Demographic, clinical and operative variables were analysed as predictive factors for success.ResultsA total of 27 patients (51.9% female) with a mean age of 53.7 years underwent DREZotomy. The main cause of pain was brachial plexus injury (BPI) (55.6%) followed by neoplasms (18.5%). The mean time of pain evolution was 8.4 years with a mean intensity of 8.7 according to the VAS, even though 63% of the patients had previously received neurostimulation therapy. Favourable outcome (≥ 50% pain reduction in the VAS) was observed in 77.8% of patients during the postoperative period and remained in 59.3% of patients after 22 months average follow-up (mean reduction of 4.9 points). This allowed for a reduction in routine analgesic treatment in 70.4% of them. DREZotomy in BPI-related pain presented a significantly higher success rate (93%) than the other pathologies (41.7%) (p = .001). No association was observed between outcome and age, gender, DREZ technique, duration of pain or previous neurostimulation therapies. There were six neurological complications, four post-operative transient neurological deficits and two permanent deficits.ConclusionDorsal root entry zone surgery is effective and safe for treating patients with deafferentation pain, especially after brachial plexus injury. It can be considered an alternative treatment after failed neurostimulation techniques for pain control. However, its indication should be considered as the first therapeutic option after medical therapy failure due to its good long-term results. 相似文献
5.
6.
7.
8.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
9.
10.